Loading
Papillomavirus Infections / Papillomavirus Vaccines / Vaccine · Journal article
Human Vaccines & Immunotherapeutics · July 8, 2026
Reinforces what was already believed, rather than introducing something new.
Among 893 vaccinated Chinese women, post-vaccination HPV prevalence was 8.51%, with the most common high-risk types being HPV52, HPV59, and HPV58—genotypes not covered by administered vaccines. Women who initiated vaccination after sexual debut, had pre-vaccination HPV infection, were older, or married demonstrated significantly higher odds of post-vaccination HPV infection.
Cross-sectional study. Women who received HPV vaccine and had thin-layer liquid-based cytology test and HPV genotype testing before HPV vaccination. Intervention: HPV vaccination. n = 893. China.
Post-vaccination HPV prevalence was 8.51% among 893 vaccinated women Women aged ≥40 years had 2.92-fold higher odds of post-vaccination HPV infection Receiving first vaccine dose after sexual debut was associated with 2.57-fold higher odds of HPV infection
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Findings support vaccinating before sexual debut and continuing HPV screening post-vaccination, particularly for women vaccinated after sexual activity or with prior HPV infection. Residual HPV prevalence reflects non-vaccine genotypes, underscoring the continued need for screening even among vaccinated women.
Cross-sectional study with 893 participants demonstrates reduced post-vaccination HPV prevalence and identifies expected risk factors, reinforcing established vaccination strategies.
As stated by the source record.
Quoted from the source exactly as published.
Findings support vaccinating before sexual debut and continuing HPV screening post-vaccination, particularly for women vaccinated after sexual activity or with prior HPV infection. Residual HPV prevalence reflects non-vaccine genotypes, underscoring the continued need for screening even among vaccinated women.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study aimed to evaluate human papillomavirus (HPV) prevalence and genotype distribution among vaccinated women and to identify the factors associated with post-vaccination HPV infection. Women who received HPV vaccine and had the thin-layer liquid-based cytology test (TCT) and HPV genotype testing before HPV vaccination were recruited. Each participant was required to complete an online questionnaire, and cervical specimen was collected for TCT and HPV genotype testing. The epidemiology of HPV infection and genotype was described. The factors associated with HPV infection post-vaccination were identified through multivariate analysis, presenting the adjusted odds ratio (AOR) with its 95% confidence interval (95%CI). A total of 893 eligible women participated. The prevalence of HPV post-vaccination was 8.51%. The common high-risk HPV (hr-HPV) were HPV52, HPV59, HPV58 and the common low-risk HPV (lr-HPV) was HPV53. Factors associated with HPV infection post-vaccination included aged ≥40y (AOR = 2.92), married status (AOR = 1.56), receiving the first dose of HPV vaccine after sexual debut (OR = 2.57), lr-HPV positive pre-vaccination (AOR = 2.35) and hr-HPV positive pre-vaccination (AOR = 5.72). The prevalence of HPV post-vaccination was lower than that of pre-vaccination and the common genotypes changed to those not covered by HPV vaccine administrated. Age, marital status, timing of HPV vaccination and prior HPV infection before HPV vaccination were identified as the factors associated with HPV infection post-vaccination. Receiving HPV vaccination before sexual debut and ongoing HPV screening after vaccination were recommended.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.